# Thyroid 2020 Case Scenarios Answer Sheets

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 1** | | | | | | | | | |
| Primary Site | C73.9 | Histology | | | 8260 | Behavior | | 3 | |
| MP Rule | M18 | H Rule | | | H23 |  | |  | |
| Clinical Grade | 9 | Pathological Grade | | | 9 | Post-therapy Grade | |  | |
| **Stage/ Prognostic Factors** | | | | | | | | | |
| Age | | 48 | | Tumor Size Clin | | | 999 | | |
| Clinical T | |  | | Tumor Size Path | | | 007 | | |
| Clinical T Suffix | |  | | Tumor Size Summary | | | 007 | | |
| Clinical N | |  | | Regional Nodes Pos | | | 00 | | |
| Clinical N Suffix | |  | | Regional Nodes Ex | | | 03 | | |
| Clinical M | |  | |  | | |  | | |
| Clinical Stage | | 99 | | EOD Ext | | | 100 | | |
|  | |  | | EOD LN | | | 000 | | |
| Pathological T | | pT1a | | EOD Mets | | | 00 | | |
| Pathological T Suffix | | (m) | |  | | |  | | |
| Pathological N | | pN0a | | Summary Stage 2018 | | | 1-Localized | | |
| Pathological N Suffix | |  | |  | | |  | | |
| Pathological M | | cM0 | |  | | |  | | |
| Pathological Stage | | 1 | |  | | |  | | |
| **Treatment** | | | | | | | | | |
| Diagnostic Staging Procedure | | | 00 | **Systemic Therapy Codes** | | | | |  |
| **Surgery Codes** | | |  | Chemotherapy | | | | | 00 |
| Surgical Procedure of Primary Site | | | 50 | Hormone Therapy | | | | | 01 |
| Scope of Regional Lymph Node Surgery | | | 4 | Immunotherapy | | | | | 00 |
| Surgical Procedure/ Other Site | | | 0 | Hematologic Transplant/ Endocrine Procedure | | | | | 00 |
|  | | |  | Systemic/Surgery Sequence | | | | | 3 |
| Radiation | | | | | | | | | |
| Radiation Primary Tx Volume | | | 00 | Dose per Fraction | | | | |  |
| Radiation to Primary LN’s | | |  | Number of Fractions | | | | |  |
| Radiation Tx Modality | | | 00 | Total Dose | | | | |  |
| Radiation Planning Technique | | |  | Number of Phases | | | | |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 2a** | | | | | | | | | |
| Primary Site | C73.9 | Histology | | | 8345 | Behavior | | 3 | |
| MP Rule | M17 | H Rule | | | H23 |  | |  | |
| Clinical Grade | 9 | Pathological Grade | | | 9 | Post-therapy Grade | |  | |
| **Stage/ Prognostic Factors** | | | | | | | | | |
| Age | | 60 | | Tumor Size Clin | | | 010 | | |
| Clinical T | | cT1a | | Tumor Size Path | | | 007 | | |
| Clinical T Suffix | | (s) | | Tumor Size Summary | | | 007 | | |
| Clinical N | | cN0b | | Regional Nodes Pos | | | 00 | | |
| Clinical N Suffix | |  | | Regional Nodes Ex | | | 05 | | |
| Clinical M | | cM0 | |  | | |  | | |
| Clinical Stage | | 1 | | EOD Ext | | | 100 | | |
|  | |  | | EOD LN | | | 000 | | |
| Pathological T | | pT1a | | EOD Mets | | | 00 | | |
| Pathological T Suffix | | (m) | |  | | |  | | |
| Pathological N | | pN0a | | Summary Stage 2018 | | | 1-Localized | | |
| Pathological N Suffix | |  | |  | | |  | | |
| Pathological M | | cM0 | |  | | |  | | |
| Pathological Stage | | 1 | |  | | |  | | |
| **Treatment** | | | | | | | | | |
| Diagnostic Staging Procedure | | | 02 | **Systemic Therapy Codes** | | | | |  |
| **Surgery Codes** | | |  | Chemotherapy | | | | | 00 |
| Surgical Procedure of Primary Site | | | 50 | Hormone Therapy | | | | | 01 |
| Scope of Regional Lymph Node Surgery | | | 5 | Immunotherapy | | | | | 00 |
| Surgical Procedure/ Other Site | | | 0 | Hematologic Transplant/ Endocrine Procedure | | | | | 00 |
|  | | |  | Systemic/Surgery Sequence | | | | | 3 |
| Radiation | | | | | | | | | |
| Radiation Primary Tx Volume | | | 98 (other) | Dose per Fraction | | | | | 999998 |
| Radiation to Primary LN’s | | | 00 | Number of Fractions | | | | | 1 |
| Radiation Tx Modality | | | 13 (RAI) | Total Dose | | | | | 9999998 |
| Radiation Planning Technique | | | 88 | Number of Phases | | | | | 1 |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 2b** | | | | | | | | | |
| Primary Site | C73.9 | Histology | | | 8260 | Behavior | | 3 | |
| MP Rule | M17 | H Rule | | | H11 |  | |  | |
| Clinical Grade | 9 | Pathological Grade | | | 9 | Post-therapy Grade | |  | |
| **Stage/ Prognostic Factors** | | | | | | | | | |
| Age | | 60 | | Tumor Size Clin | | | 999 | | |
| Clinical T | |  | | Tumor Size Path | | | 001 | | |
| Clinical T Suffix | |  | | Tumor Size Summary | | | 001 | | |
| Clinical N | |  | | Regional Nodes Pos | | | 00 | | |
| Clinical N Suffix | |  | | Regional Nodes Ex | | | 05 | | |
| Clinical M | |  | |  | | |  | | |
| Clinical Stage | | 99 | | EOD Ext | | | 100 | | |
|  | |  | | EOD LN | | | 000 | | |
| Pathological T | | pT1a | | EOD Mets | | | 00 | | |
| Pathological T Suffix | | (s) | |  | | |  | | |
| Pathological N | | pN0a | | Summary Stage 2018 | | | 1-Localized | | |
| Pathological N Suffix | |  | |  | | |  | | |
| Pathological M | | cM0 | |  | | |  | | |
| Pathological Stage | | 1 | |  | | |  | | |
| **Treatment** | | | | | | | | | |
| Diagnostic Staging Procedure | | | 00 | **Systemic Therapy Codes** | | | | |  |
| **Surgery Codes** | | |  | Chemotherapy | | | | | 00 |
| Surgical Procedure of Primary Site | | | 50 | Hormone Therapy | | | | | 01 |
| Scope of Regional Lymph Node Surgery | | | 5 | Immunotherapy | | | | | 00 |
| Surgical Procedure/ Other Site | | | 0 | Hematologic Transplant/ Endocrine Procedure | | | | | 00 |
|  | | |  | Systemic/Surgery Sequence | | | | | 3 |
| Radiation | | | | | | | | | |
| Radiation Primary Tx Volume | | | 98 (other) | Dose per Fraction | | | | | 999998 |
| Radiation to Primary LN’s | | | 00 | Number of Fractions | | | | | 1 |
| Radiation Tx Modality | | | 13 (RAI) | Total Dose | | | | | 9999998 |
| Radiation Planning Technique | | | 88 | Number of Phases | | | | | 1 |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 3** | | | | | | | | | |
| Primary Site | C73.9 | Histology | | | 8021 | Behavior | | 3 | |
| MP Rule | M2 | H Rule | | | H11 |  | |  | |
| Clinical Grade | 4 | Pathological Grade | | | 4 | Post-therapy Grade | |  | |
| **Stage/ Prognostic Factors** | | | | | | | | | |
| Age | | 58 | | Tumor Size Clin | | | 060 | | |
| Clinical T | | cT3b | | Tumor Size Path | | | 088 | | |
| Clinical T Suffix | | (s) | | Tumor Size Summary | | | 088 | | |
| Clinical N | | cN1a | | Regional Nodes Pos | | | 02 | | |
| Clinical N Suffix | | (f) | | Regional Nodes Ex | | | 15 | | |
| Clinical M | | cM0 | |  | | |  | | |
| Clinical Stage | | 4B | | EOD Ext | | | 400 | | |
|  | |  | | EOD LN | | | 300 | | |
| Pathological T | | pT4a | | EOD Mets | | | 00 | | |
| Pathological T Suffix | | (s) | |  | | |  | | |
| Pathological N | | pN1a | | Summary Stage 2018 | | | 4 | | |
| Pathological N Suffix | |  | |  | | |  | | |
| Pathological M | | cM0 | |  | | |  | | |
| Pathological Stage | | 4B | |  | | |  | | |
| **Treatment** | | | | | | | | | |
| Diagnostic Staging Procedure | | | 00 | **Systemic Therapy Codes** | | | | |  |
| **Surgery Codes** | | |  | Chemotherapy | | | | | 03 |
| Surgical Procedure of Primary Site | | | 23 | Hormone Therapy | | | | | 01 |
| Scope of Regional Lymph Node Surgery | | | 5 | Immunotherapy | | | | | 00 |
| Surgical Procedure/ Other Site | | | 0 | Hematologic Transplant/ Endocrine Procedure | | | | | 0 |
|  | | |  | Systemic/Surgery Sequence | | | | | 3 |
| Radiation | | | | | | | | | |
| Radiation Primary Tx Volume | | | 00 | Dose per Fraction | | | | |  |
| Radiation to Primary LN’s | | |  | Number of Fractions | | | | |  |
| Radiation Tx Modality | | | 00 | Total Dose | | | | |  |
| Radiation Planning Technique | | |  | Number of Phases | | | | |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 4** | | | | | | | | | |
| Primary Site | C73.9 | Histology | | | 8337 | Behavior | | 3 | |
| MP Rule | M2 | H Rule | | | H11 |  | |  | |
| Clinical Grade | 9 | Pathological Grade | | | 3 | Post-therapy Grade | |  | |
| **Stage/ Prognostic Factors** | | | | | | | | | |
| Age | | 70 | | Tumor Size Clin | | | 045 | | |
| Clinical T | | cT3a | | Tumor Size Path | | | 045 | | |
| Clinical T Suffix | | (s) | | Tumor Size Summary | | | 045 | | |
| Clinical N | | cN0b | | Regional Nodes Pos | | | 98 | | |
| Clinical N Suffix | |  | | Regional Nodes Ex | | | 00 | | |
| Clinical M | | pM1 | |  | | |  | | |
| Clinical Stage | | 4B | | EOD Ext | | | 200 | | |
|  | |  | | EOD LN | | | 050 | | |
| Pathological T | | pT3a | | EOD Mets | | | 70 | | |
| Pathological T Suffix | | (s) | |  | | |  | | |
| Pathological N | | pNX | | Summary Stage 2018 | | | 7 distant mets | | |
| Pathological N Suffix | |  | |  | | |  | | |
| Pathological M | | pM1 | |  | | |  | | |
| Pathological Stage | | 4B | |  | | |  | | |
| **Treatment** | | | | | | | | | |
| Diagnostic Staging Procedure | | | 00 | **Systemic Therapy Codes** | | | | |  |
| **Surgery Codes** | | |  | Chemotherapy | | | | | 00 |
| Surgical Procedure of Primary Site | | | 50 | Hormone Therapy | | | | | 01 |
| Scope of Regional Lymph Node Surgery | | | 0 | Immunotherapy | | | | | 00 |
| Surgical Procedure/ Other Site | | | 0 | Hematologic Transplant/ Endocrine Procedure | | | | | 0 |
|  | | |  | Systemic/Surgery Sequence | | | | | 3 |
| Radiation | | | | | | | | | |
| Radiation Primary Tx Volume | | | 98 (other) | Dose per Fraction | | | | | 999998 |
| Radiation to Primary LN’s | | | 00 | Number of Fractions | | | | | 1 |
| Radiation Tx Modality | | | 13 (RAI) | Total Dose | | | | | 9999998 |
| Radiation Planning Technique | | | 88 | Number of Phases | | | | | 1 |